Selicrelumab |
Catalog No.GC65512 |
Selicrelumab es un anticuerpo agonista CD40, induce cambios en el microambiente tumoral. Selicrelumab se puede utilizar para la investigaciÓn del cÁncer de pÁncreas y el estudio neoadyuvante.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1622140-49-1
Sample solution is provided at 25 µL, 10mM.
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study[1].
[1]. Katelyn T Byrne, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *